Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
about
Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteinsRecombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumorsA deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.Immunotoxins for leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.Update on antigen-specific immunotherapy of acute myeloid leukemia.Biological activities of ribosome-inactivating proteins and their possible applications as antimicrobial, anticancer, and anti-pest agents and in neuroscience research.Recent developments in immunotherapy of acute myeloid leukemia.Antibody-mediated delivery of therapeutics for cancer therapy.The future of antiviral immunotoxins.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Gemtuzumab ozogamicin in acute myeloid leukemia.Development and validation of an enzyme-linked immunosorbent assay for the quantification of gelonin in mouse plasma.Clinical targeting recombinant immunotoxins for cancer therapyTWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.Improved Protein Toxin Delivery Based on ATTEMPTS Systems.Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations.The progress and current status of immunotherapy in acute myeloid leukemia.Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.The role of CD33 as therapeutic target in acute myeloid leukemia.
P2860
Q26799861-4C2A804D-8738-48AF-8312-258F4EBD7249Q34345494-1D623BC1-AD7C-4A57-B22F-8D59FBD5C604Q36979140-1B8A38A0-C6C3-43FA-B6D6-F9163E7CB955Q37247862-83C81212-574A-4C02-9730-B59DD00F4A56Q37367958-E1C967F1-CCB5-4C1B-AA81-06F71F7A1698Q37593171-9D46EF8C-F3A6-46D3-ACEF-420D40014361Q37698916-4769CC89-4E0E-4F8D-B059-313DF3C76EC3Q37709336-A48DC8D3-8E66-4EC8-8350-07AF7865343AQ38109541-9D61409F-C342-48C1-B3D7-AD33BC8406C6Q38262399-FF5DC3F4-4D1D-423B-A3AB-96A8F80A2AABQ38432103-F5368B3A-403A-4F98-B5B4-0F937E303B4FQ38591156-14C26C12-C79D-44EC-BC9A-37112B8C6E3AQ38661895-E522E9C4-7447-48D2-920F-7B90DA5D4C32Q38665425-70D733F9-F5FC-450A-A531-2BA7AF19B31DQ38686601-49796A4D-2258-468E-AA8E-D9B11CF413CFQ38700209-EF2F481F-7160-420D-BFC0-C80E59703C8EQ38728718-F10A24E9-B1C2-4038-81A5-C69357725508Q39803785-78920F4C-2D6F-4628-927F-22AEDE719DC7Q41149227-F092A809-B67D-4706-B06C-9913410C4D9AQ42004462-82791A81-E04D-4D2C-91B4-CA2749177AD1Q46409297-D0CEE617-91AC-44F0-9F85-1142E8BA28AFQ47114983-49902EC0-C8EE-4DCF-A16A-C33048B30992Q47231221-FD02DC7E-2A26-4460-91B9-D49E86A7F437Q47590707-497AEAE2-D8B5-4863-82C8-440063ABEA0BQ50865525-92F9B369-FE34-4BE9-ABC8-D1CA70178AF5Q53056603-B474D812-E729-4127-8D2A-69E934870E6F
P2860
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@ast
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@en
type
label
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@ast
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@en
prefLabel
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@ast
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@en
P2093
P2860
P50
P1433
P1476
Phase 1 study of an anti-CD33 ...... advanced myeloid malignancies.
@en
P2093
Emil J Freireich
Guillermo Garcia-Manero
Michael G Rosenblum
Moshe Talpaz
Naval Daver
P2860
P304
P356
10.3324/HAEMATOL.2012.071092
P577
2012-08-08T00:00:00Z